Eli Lilly and Company

Elanco US Inc.

Timothy Barrett Durham

Richard Duane Johnston

James Lee Toth

David Andrew Coates

Timothy Alan Shepherd

Patrick Gianpietro Spinazze

Steven Marc Massey

Robert Dean Dally

Douglas Richard Stack

James R McCarthy

Michael Robert Wiley

Kenneth Jeff Thrasher

Jefferson Ray McCowan

Patric James Hahn

Zhipei Wu

Ana Belen Bueno Melendo

Todd Jonathan Kohn

Maria Rosario Gonzalez-Garcia

Kenneth James Henry, Jr

Harold Burns Brooks

Kevin Robert Fales

Chong Si

Jon Andre Erickson

Junliang Hao

Kwame Frimpong

Howard Barff Broughton

Frank George Njoroge

Jothirajah Marimuthu

The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds

The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Disubstituted pyrazole compounds

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

2,6-diamino pyridine compounds

1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers

The present invention provides compounds having the formula: wherein Ris selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof. 

Aggrecanase inhibitors

The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation. 

3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors

Growing community of inventors

Indianapolis, IN, United States of America

Timothy Barrett Durham